Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · IEX Real-Time Price · USD
2.300
-0.170 (-6.88%)
Apr 12, 2024, 4:00 PM EDT - Market closed

Company Description

ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder.

The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD.

ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Atai Life Sciences N.V.
Atai Life Sciences logo
Country Germany
Founded 2018
IPO Date Jun 18, 2021
Industry Biotechnology
Sector Healthcare
Employees 133
CEO Florian Brand

Contact Details

Address:
Wallstrasse 16
Berlin, 2M 10179
Germany
Phone (617)-699-5876
Website atai.life

Stock Details

Ticker Symbol ATAI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001840904
CUSIP Number N0731H103
ISIN Number NL0015000DX5
SIC Code 2834

Key Executives

Name Position
Christian Angermayer Founder and Chairman of the Supervisory Board
Florian Brand Co-founder and Chief Executive Officer
Dr. Srinivas G. Rao M.D., Ph.D. Co-Founder and Chief Scientific Officer
Stephen B. Bardin Advisor
Anne Johnson Chief Financial Officer
Dr. Michael Raven Ph.D. Senior Vice President of Operations
Frank Stegert Vice President of Investment and Venture Management
Ryan Barrett Senior Vice President, General Counsel and Corporate Secretary
Dr. Glenn Short Ph.D. Senior Vice President of Early Development
Dr. Sahil V. Kirpekar M.D. Chief Business Officer

Latest SEC Filings

Date Type Title
Apr 8, 2024 144 Filing
Apr 5, 2024 144 Filing
Apr 4, 2024 144 Filing
Apr 4, 2024 144 Filing
Apr 3, 2024 144 Filing
Mar 28, 2024 10-K Annual Report
Mar 28, 2024 8-K Current Report
Mar 12, 2024 4 Statement of changes in beneficial ownership of securities
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 6, 2024 8-K Current Report